Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CP-320626 is an effective inhibitor of glycogen phosphorylase A (LGPA) in the human liver and GPA in the human muscle. Can act synergistically with glucose. It is a possible target for the treatment of type 2 diabetes.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | CP-320626 is an effective inhibitor of glycogen phosphorylase A (LGPA) in the human liver and GPA in the human muscle. Can act synergistically with glucose. It is a possible target for the treatment of type 2 diabetes. |
Synonyms | CP 320626 |
Molecular Weight | 443.9 |
Formula | C23H23ClFN3O3 |
CAS No. | 186430-23-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CP-320626 186430-23-9 CP 320626 CP320626 inhibitor inhibit